Literature DB >> 27556705

Myeloma minimal residual disease testing in the United States: Evidence of improved standardization.

Dalia Salem1, Maryalice Stetler-Stevenson1, Constance Yuan1, Ola Landgren2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27556705      PMCID： PMC5118175          DOI： 10.1002/ajh.24540

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  7 in total

1.  Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity.

Authors:  Aaron Flanders; Maryalice Stetler-Stevenson; Ola Landgren
Journal:  Blood       Date:  2013-08-08       Impact factor: 22.113

2.  Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.

Authors:  Maryalice Stetler-Stevenson; Bruno Paiva; Lloyd Stoolman; Pei Lin; Jeffrey L Jorgensen; Alberto Orfao; Jacques Van Dongen; Andy C Rawstron
Journal:  Cytometry B Clin Cytom       Date:  2015-07-06       Impact factor: 3.058

3.  Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium.

Authors:  Ola Landgren; Nicole Gormley; Danielle Turley; Roger G Owen; Andy Rawstron; Bruno Paiva; David Barnett; Maria Arroz; Paul Wallace; Brian Durie; Constance Yuan; Ahmet Dogan; Maryalice Stetler-Stevenson; Gerald E Marti
Journal:  Am J Hematol       Date:  2014-12       Impact factor: 10.047

4.  Assessment of minimal residual disease in myeloma and the need for a consensus approach.

Authors:  Andy C Rawstron; Bruno Paiva; Maryalice Stetler-Stevenson
Journal:  Cytometry B Clin Cytom       Date:  2015-09-23       Impact factor: 3.058

5.  Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.

Authors:  Maria Arroz; Neil Came; Pei Lin; Weina Chen; Constance Yuan; Anand Lagoo; Mariela Monreal; Ruth de Tute; Jo-Anne Vergilio; Andy C Rawstron; Bruno Paiva
Journal:  Cytometry B Clin Cytom       Date:  2015-06-02       Impact factor: 3.058

6.  Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.

Authors:  Andy C Rawstron; J Anthony Child; Ruth M de Tute; Faith E Davies; Walter M Gregory; Sue E Bell; Alexander J Szubert; Nuria Navarro-Coy; Mark T Drayson; Sylvia Feyler; Fiona M Ross; Gordon Cook; Graham H Jackson; Gareth J Morgan; Roger G Owen
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

Review 7.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Authors:  Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau
Journal:  Lancet Oncol       Date:  2016-08       Impact factor: 41.316
  7 in total
  9 in total

Review 1.  Monitoring minimal residual disease in the bone marrow using next generation sequencing.

Authors:  Even H Rustad; Eileen M Boyle
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-17       Impact factor: 3.020

Review 2.  Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Joseph D Tario; Paul K Wallace
Journal:  Clin Lab Med       Date:  2017-12       Impact factor: 1.935

3.  Monitoring of Measurable Residual Disease in Multiple Myeloma by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Paul K Wallace
Journal:  Curr Protoc Cytom       Date:  2019-07-17

Review 4.  Is molecular remission the goal of multiple myeloma therapy?

Authors:  Faith E Davies
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

5.  What to do with minimal residual disease testing in myeloma.

Authors:  Elisabet E Manasanch
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.

Authors:  Hervé Avet-Loiseau; Heinz Ludwig; Ola Landgren; Bruno Paiva; Chris Morris; Hui Yang; Kefei Zhou; Sunhee Ro; Maria-Victoria Mateos
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-10-09

7.  Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.

Authors:  J Flores-Montero; L Sanoja-Flores; B Paiva; N Puig; O García-Sánchez; S Böttcher; V H J van der Velden; J-J Pérez-Morán; M-B Vidriales; R García-Sanz; C Jimenez; M González; J Martínez-López; A Corral-Mateos; G-E Grigore; R Fluxá; R Pontes; J Caetano; L Sedek; M-C Del Cañizo; J Bladé; J-J Lahuerta; C Aguilar; A Bárez; A García-Mateo; J Labrador; P Leoz; C Aguilera-Sanz; J San-Miguel; M-V Mateos; B Durie; J J M van Dongen; A Orfao
Journal:  Leukemia       Date:  2017-01-20       Impact factor: 11.528

8.  Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma.

Authors:  Even H Rustad; Malin Hultcrantz; Venkata D Yellapantula; Theresia Akhlaghi; Caleb Ho; Maria E Arcila; Mikhail Roshal; Akshar Patel; Denise Chen; Sean M Devlin; Austin Jacobsen; Ying Huang; Jeffrey E Miller; Elli Papaemmanuil; Ola Landgren
Journal:  PLoS One       Date:  2019-03-22       Impact factor: 3.240

9.  Characterization of circulating myeloma tumor cells by next generation flowcytometry in scleromyxedema patient: a case report.

Authors:  Ruba Y Taha; Saba Hasan; Firyal Ibrahim; Yannick Chantran; Hesham El Sabah; Siveen Sivaraman; Issam Al Bozom; Ahmad Al Sabbagh; Laurent Garderet; Halima El Omri
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.